Post

MEI and Kyowa Kirin to discontinue development of zandelisib outside Japan

Based on findings from the MIRAGE and TIDAL trials, Kyowa Kirin will seek marketing authorisation in Japan.

Managing drug shortages: Getting medicines to patients in need

Patients around the world are experiencing drug shortages, with production still recovering from the disruption caused by Covid-19, the war in Ukraine, and rising energy costs. Tanner Pharma is tackling these issues head-on, managing disruptions and ensuring that a range of treatments reach patients wherever they are.